

Effectively Communicating Science: Centering Diverse Needs and Engendering Trust

Consuelo H. Wilkins, MD, MSCI

Chief Equity Officer
Professor of Medicine
Vanderbilt University Medical Center

President's Council of Advisors on Science and Technology
March 24, 2022



COVID-19 Health Equity Workstream


Consuelo H. Wilkins, Elisa Friedman, André L. Churchwell, Tiercy Fortenberry, Amber Humphrey, Pam Jones, Sunil Kripalani, Larry Prisco, Jill Pulley, Terrell Smith

CLID CTDEAM	ODIECTIVES
Effective Communication	 Effectively communicate COVID-19 risks and preventative strategies to: Individuals at risk for health inequities – minoritized racial/ethnic groups, socioeconomically disadvantaged, people w preferred language not English Employees: including nutrition, maintenance, environmental services
Equitable Testing	 Provide/facilitate timely testing Report aggregate test results by key demographics including age, gender, race/ethnicity, preferred language, and ZIP code
Equitable Care	 Provide high quality care that does not vary by race/ethnicity, gender, SES Effectively communicate post-discharge and facilitate transitions of care Report aggregate outcomes by age, gender, and race/ethnicity, ZIP
Inclusivity in Clinical Trials	 Increase awareness of importance of clinical research for COVID-19 given there is no proven effective therapy Engage/enroll racial/ethnic minorities, others socially disadvantaged
Inclusive Implementation of Telehealth	 Effectively use telehealth to provide care for patients including those with limited health literacy, English proficiency, internet access Increase adoption of telehealth among racial/ethnic minorities, patients with, limited English proficiency, and underserved rural communities



Innovations in Care Delivery

Most Covid-19 Cases at Vanderbilt University Medical Center (as of July 1, 2020)



ARTICLE

A Systems Approach to Addressing Covid-19 Health Inequities

Consuelo H. Wilkins, MD, MSCI, Elisa C. Friedman, MS, André L. Churchwell, MD, Jennifer M. Slayton, MSN, RN, Pam Jones, DNP, RN, NEA-BC, FAAN, Jill M. Pulley, MBA, Sunil Kripalani, MD, MSc, SFHM

Socioeconomic Data of ZIP Code with Highest Number of					
Covid-19 Cases Compared with Nashville Metropolitan Area					
	ZIP Code	Nashville, TN			
	37013	Metro Area			
Population	97,819	1,932,099			
Vanderbilt Covid-19 cases (7.1.20)	381	2,470			
Black/African American	35%	15%			
Hispanic/Latino	16%	7%			
Asian/Asian American	4%	3%			
High school or equivalent	87.2%	89.5%			
Language other than English spoken at home	30.3%	10.3%			
Foreign born	25%	8%			
Median home value	\$167,900	\$217,500			
Household size	2.8	2.6			
Adults employed	73.1%	67.6%			
Per capita income	\$25,568	\$33,606			
Persons below poverty line	15.7%	12.4%			

Source: Socioeconomic data from Census Reporter. 2020. Accessed November 14, 2020. https://censusreporter.org/profiles/86000US37013-37013/ and https://censusreporter.org/profiles/31000US34980-nashville-davidson-murfreesboro-franklin-tn-metro-area/. Map from Statistical Atlas. Demographics. 2020. Accessed November 14, 2020. https://statisticalatlas.com/county/Tennessee/Davidson-County/Race-and-Ethnicity#data-map/tract NEJM Catalyst (catalyst.nejm.org) © Massachusetts Medical Society

VUMC SARS CoV-2 1	ests by Ra	ce, Ethnic	ity, Lang	uage –	1.12.2	022	
	Population	SARS-Cov-2		(+)SARS CoV-2	2	Within-group (+)	Within group + through 7.1.21
	% Nashville MSA population total: 1,933,860	n (% of 340,645)		n (% of	49,180)		
RACE/ETHNICITY							
White	76.7%	225,767	(66.3%)	28,699	(58.4%)	12.7%	10.1%
Black/African American	15.2%	41,249	(12.1%)	6,157	(12.5%)	14.9%	9.6%
Hispanic / Latino	7.6%	19,686	(5.8%)	2,840	(5.8%)	14.4%	11.8%
Asian	3.0%	6,340	(1.9%)	879	(1.8%)	13.9%	13.0%
American Indian	0.2%	666	(0.2%)	95	(0.2%)	14.3%	10.8%
Other	2.4%	10,568	(3.1%)	1,411	(2.9%)	13.4%	9.9%
Unknown Race	N/A	56,055	(16.5%)	11,939	(24.3%)	21.3%	18.7%





	Population	SARS-Cov-2	(+)SARS Co	V-2	Within-group (+)	Within group + through 7.1.21
	% Nashville MSA population total: 1,933,860	n (% of 340,645)	n (%	of 49,180)		
Preferred Language						
English	88.3%	322,576 (94.7%)	46,161	(93.9%)	14.3%	11.2%
All Languages other than						
English (102)	11.7%	16,749 (4.9%)	3,019	(6.1%)	18.0%	14.3%
Spanish	6.4%	10,482(3.1%)	1,632	(3.3%)	15.6%	13.8%
Arabic	1.0%	3,472(1.0%)	660	(1.3%)	19.0%	15.0%
Nepali	< 1%	334(0.1%)	93	(0.2%)	27.8%	29.3%
Unknown language	N/A	1,320(0.4%)	246	(0.5%)	18.6%	10.7%





Working with Trusted Community Partners to Deliver COVID-19 Information



VANDERBILT V UNIVERSITY
MEDICAL CENTER

يقدم مركز المحبة مع مستشفى فاندر بيلت لايف عن

كيف احمى بيتى من الكورونا: الحمل والأطفال

١٨ يونيو الساعة ٥ مساء

سيكون معفا

Dr. Alex Jahangir: Chair of Metro Nashville's COVID-19 Task Force, Director of VUMC's Orthopedic Trauma Division

Dr. Soheyl Asadsangabi: Asst. Professor at Vanderbilt School of Medicine
Ms. Hafsah Alashmaly: Registered Nurse at VUMC's OBGYN Department
Ms. Rifka Awad: Medical Interpreter at VUMC



Charla sobre COVID- 19, Fé y salud

Alianza Meharry-Vanderbilt, Coalición para las Desigualdades en Salud y la Colaboración entre Fe y Salud



Nashville Health Disparities Coalition

COVID-19 Community-Led Communications

Elmahaba Center:

"COVID-19: Pregnancy & Newborns" Livestream in Arabic



June 18, 2020 13.2k views 28 shares

46 comments

Conexión Américas:

"What is Telehealth?"
Video in Spanish



April 27, 2020

9.7k views

165 likes

20 shares

MVA, Nashville Health Disparities Coalition:

"COVID-19: Fe y Salud"

<u>Livestream in</u>

Spanish



June 4, 2020

15.2k views

133 likes

22 shares

How Effective Are The Covid-19 Vaccines?

Estimated effectiveness at Covid-19 prevention based on interim data from late-stage clinical trials*



- * Some trials are ongoing and findings have not been peer-reviewed. Efficacy may differ with new Covid-19 variants.
- ** ChAdOx1 nCoV-2019 efficacy climbs to 90% with a second dose. JNJ's U.S. efficacy was 72%. Coronavac data based on Brazil trials.

Sources: Respective companies, The Lancet, Butantan Institute










How might you interpret this data?



Scale items mapped to trust dimensions with item mean differences by race/ethnicity category					
••	Theoretical Dimensions from Literature	Practical Dimensions from Focus Group Data	Item Mean Differences by Category B = Black; H/L = Hispanic/Latino; W = white; Cl confidence interval		
Trust Subscale					
1. Medical researchers tell people everything they need to know about being in a research study.	Honesty, Communication	Secrecy	H/L < W: -0.361 (95% CI -0.646, -0.077)		
4. Medical researchers would never give someone something that would hurt them, just to study how it works in people.	Honesty, Fidelity		B < W: -0.391 (95% CI -0.654, -0.129)		
7. Participation in medical research benefits society.		Benefit	B < W: -0.247 (95% CI -0.369, -0.125)		
10. Medical researchers only do research on people who know it is happening.	Fidelity, Safety	Risk/Harms	H/L < W: -0.591 (95% CI -0.880, -0.302)		
14. My physician would not ask me to be in a medical research study if he/she thought it would hurt me.	Confidence, Fidelity, Safety	Risk/Harms	B < W: -0.425 (95% CI -0.630, -0.220)		
Distrust Subscale					
8. Medical research is secretly designed to give diseases to minority groups. 12. Medical researchers would lie to people to convince them to be in a research study.	Fairness, Systems Trust, Safety Honesty	Risk/Harms, Secrecy	H/L > W: 0.413 (95% CI 0.183, 0.644) B > W: 0.560 (95% CI 0.376, 0.745) B > W: 0.425 (95% CI 0.210, 0.641)		
16. Medical researchers will share my personal info with anybody else they want to, even if I don't tell them they can do that.	Confidentiality	Privacy	B > W: 0.362 (95% CI 0.168, 0.557)		

Table 1: Race/Ethnicity of Participants in Pfizer-BioNTech and Moderna COVID-19 Vaccine Clinical Trials					
	Total US Population Age 16+	Pfizer-BioNTech*	Moderna 27,817		
Total	258 million	40,277			
Race					
White	73.6%	81.9%	79.4%		
Black	12.3%	9.8%	9.7%		
Asian	5.9%	4.4%	4.7%		
American Indian/Alaska Native	0.8%	0.6%	0.8%		
Native Hawaiian or Other Pacific Islander	0.2%	0.2%	0.2%		
Ethnicity					
Hispanic	17.6%	26.2%	20.0%		
Non-Hispanic	82.4%	73.2%	79.1%		

NOTES: *Pfizer-BioNTech data are for all participants globally; of which 76.7% are in the United States. Pfizer results provided for Phase 2/3 trial, Moderna results for Phase 3 trial. The Pfizer trial included those ages 16 and older. The Moderna trial included those ages 18 and older.

SOURCES: Racial/ethnic distribution of total population age 16 or older based on KFF analysis of 2019 American Community Survey data; FDA, Briefing Document: Pfizer-BioNTech COVID-19 Vaccine, December 10, 2020; FDA, Briefing Document: Moderna COVID-19 Vaccine, December 17, 2020

Vaccine Readiness: Effectively Communicate and Engender

Trust

Effective Communication:

- Share accurate information from trustworthy sources
- Use clear, concise, plain language
- Deliver messaging using different modes- print, video, infographics, in-person, social media
- Provide information in multiple languages
- Develop FAQs, update based on feedback
- Use visuals reflecting authentic diversity





Vaccine Readiness: Effectively Communicate and Engender

Trust

Engender Trust:

- Acknowledge fears, concerns, historical injustices
- Be transparent about side effects and unknowns
- Use messengers experienced effectively communicating with diverse audiences
- Dispel myths with facts, without being critical of individual or group beliefs
- Partner with trusted leaders to share information
- Allow people to see themselves "someone like me"





Recommendations for Improving Science Communication

One-size-fits-all approaches do not work; may widen inequities

Who? Require diversity of research teams and stakeholders
Provide mechanisms to fund trusted messengers
Community orgs, faith leaders, community health providers
Train scientists in effective communication + cultural humility

What? Scientific information considers context and lived experiences

How? Use multiple modes -video, social media, radio Multiple languages — Transcreate

@DrCHWikintiple versions — different images and settings PCAST March 24, 2022



Image from democracyandme.org





Consuelo H. Wilkins, MD, MSCI Chief Equity Officer Vanderbilt University Medical Center consuelo.h.wilkins@vumc.org